Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer - Test2 - elhamkhani - TriplyDB

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

http://www.wikidata.org/entity/Q28372484

about

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer Cytotoxic and targeted therapy for hereditary cancers The role of preoperative systemic treatment in patients with breast cancer Liver Metastasis of a Triple-Negative Breast Cancer and Complete Remission for 5 Years After Treatment With Combined Bevacizumab/Paclitaxel/Carboplatin: Case Report and Review of the Literature Triple negative breast cancer: looking for the missing link between biology and treatments Targeting triple-negative breast cancer: optimising therapeutic outcomes Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry Systemic treatment strategies for triple-negative breast cancer.Fine tuning chemotherapy to match BRCA1 status TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer Concepts and targets in triple-negative breast cancer: recent results and clinical implications Hydrogen-rich saline attenuates chemotherapy-induced ovarian injury via regulation of oxidative stress Role of SMC1 in overcoming drug resistance in triple negative breast cancer Predicting response to preoperative chemotherapy agents by identifying drug action on modeled microRNA regulation networks Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies Optimization of Aqueous Biphasic Tumor Spheroid Microtechnology for Anti-Cancer Drug Testing in 3D Culture Somatic structural rearrangements in genetically engineered mouse mammary tumors.BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.An Integrative Genomics Approach for Associating GWAS Information with Triple-Negative Breast Cancer.Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study.Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40 A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer.A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73.Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Au nanomatryoshkas as efficient near-infrared photothermal transducers for cancer treatment: benchmarking against nanoshells Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy

P2860

Q24600350-EC68FE41-BBD8-4087-8C32-AEA4ADE31BF2 Q24644185-113CD727-9588-4573-BBBA-5B7C1F48626E Q26739366-B3B536BC-15FF-476C-B453-7ADDFB8D59F5 Q26746034-AEEE9ADB-B4AE-45C8-9648-7CB1764C528B Q26779880-6D2FD1D1-A226-4CE4-80AB-D562F1E5FB17 Q26783122-AF6D1BCC-9F5A-4060-B308-8DB75F87E9F7 Q26850892-4513F4E6-C517-4A70-981A-99866F5023F7 Q27011535-177E2B9E-693B-4F3A-8B21-2A4CF24A0C1A Q27691414-148C4AD5-EE92-4127-8F6B-1860F1325D9D Q27694529-E28A42E8-241C-4A58-812F-E5DC3B8FE7E6 Q27853147-E415355A-4FC3-425A-A55A-26D3B3AB00F8 Q28078992-F7C571AB-E082-4772-8A64-67C05D1DB951 Q28395154-A7437F82-747C-431E-B6E2-F57B6C385147 Q28533198-8CE94FAB-19FE-4F6F-9C0A-860A59EA84BA Q28539028-223B12FA-B55B-4600-8472-5363FCC144A6 Q28732256-AAB13493-F2E5-4F63-B971-58A31F37795D Q29617680-0F1BCC55-AED6-4F7C-BE99-4E20C6AB96D5 Q30403638-56B3D769-903E-4B63-971F-F2883DDD9CC2 Q30472845-9B09E5AD-B154-45B8-8530-CE76AB63B9FB Q30497664-B6C547D0-A663-429A-A44D-5DC2BC51EF28 Q31006508-44D1324E-79F4-42FA-A623-786D9C082C62 Q33355327-D3405D54-4160-4879-AA42-5E7AEB205731 Q33394861-0B46F42E-71B9-4886-8393-E1AA79003B51 Q33416887-9B6321B1-12BD-4FFB-8E52-DF4E7FA3E816 Q33422448-ECD4E290-AA2C-4500-9675-181D58EB0FC7 Q33426722-369C2B0A-BB26-48ED-ABCF-6C6CCD2067A7 Q33429434-13BFEAEE-4F36-4A96-B4EF-39CD1BE8F2EB Q33440778-2B100AD3-6903-4103-931B-7D725DA64029 Q33441772-FC83E414-7B59-4C64-ABFE-D303000599D1 Q33564013-22E9FDEF-D565-4A71-A61C-9C27158A3CB7 Q33573055-D4319B8B-EFE6-45D9-A45A-15A1F4A3FB98 Q33649918-1CEF1401-CDDD-46A6-AE4E-5472092CDD88 Q33684080-65B5A9D8-13D9-4DE3-BFEE-FD66D1E2A1F5 Q33698446-11B98837-5F0E-453F-9765-39DE7AFFC137 Q33699438-5FC3EB37-E7B0-4DA6-98B2-8193E09BE948 Q33742964-FA2B3EEF-0FC8-4AA0-BE62-FECA0D13ECD6 Q33757096-A3B04007-036A-4FC2-A735-493DFEBA2E19 Q33769821-5B8F42A1-D7AE-4293-A2F2-F61A8DFC38BF Q33824874-70736478-7DB1-46B8-B656-4F0E0D022089 Q33827045-A3E14A01-AC93-425D-8FDD-17EF690C1073

P2860

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

http://www.wikidata.org/entity/Q28372484

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

@ast

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

@en

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

@nl

type

label

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

@ast

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

@en

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

@nl

prefLabel

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

@ast

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

@en

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

@nl

P1433

Q28372484-38ECF73C-454C-4D4A-BFDE-176F5D1391EF

P1476

Q28372484-82C4F4BB-1263-49B5-AA4A-FE7144BC3B1D

P2093

Q28372484-08713251-0BC9-43D4-9093-3DBAA47911BF

Q28372484-09C14A2D-B236-43F3-95D0-9F3D2B35F751

Q28372484-11AF13E9-6930-4B2E-8C96-A61A3B74C4C9

Q28372484-1237E395-6423-46FC-9996-B185F6372C16

Q28372484-12F8EA70-32A6-403C-9809-AF168BA788A8

Q28372484-159BCB76-A512-4F8F-8B7B-57C73936E5E6

Q28372484-1EA53381-F081-43D9-BCA0-353CAC364B5F

Q28372484-33787B7D-4885-4899-84C1-DF3FFC17C4DB

Q28372484-342106CB-CB4D-4481-BC86-7173A3F26958

Q28372484-46805CA0-B699-4C55-ACEE-184FDAC5B3E2

P2860

Q28372484-01159B13-F9C7-4E25-840E-E78C3DA7CA8A

Q28372484-1641E726-3EEF-4E4E-8912-6446F28A0466

Q28372484-1E8BA59A-320B-4616-83DE-093B7C5A168F

Q28372484-20F0AC18-BB66-44BA-8598-8B0B0370088A

Q28372484-3E0C1E0B-6869-4A04-B70C-854B38DCA4CF

Q28372484-458983B2-23A0-4E3D-9877-117AA1F1A164

Q28372484-46F181E8-2F4E-4012-ADAE-173BF52A19D9

Q28372484-4969FB5E-7D6C-4485-926F-0274D716BEC8

Q28372484-50DFED81-A3D8-458C-BB30-CCDD8960E50F

Q28372484-5ADB9BAD-4012-4607-87F9-45219947C2C8

P304

Q28372484-47AD93C9-3303-4069-BC57-F93EB2F8E917

P31

Q28372484-373C9B9A-29F9-4386-998D-6925F29FFC60

P3181

Q28372484-DC98EA67-BBAC-44FF-9AAC-309B0D5C84DC

P356

Q28372484-2B843DF6-4876-47C1-8786-811F29DCAF8D

P407

Q28372484-71C2B666-1A0C-4B9A-B462-6CECFC93CC2A

P433

Q28372484-EBA25133-4C84-47DA-9B45-F9BBBB5B075F

P478

Q28372484-4B3A3542-B992-4B99-A408-7BB81933BA81

P50

Q28372484-60822388-4E8D-4694-AE58-31EC8F3CAB43

Q28372484-6FE930ED-BE67-4348-976E-34001913768A

Q28372484-e73bcec3-45fe-816a-a826-28ca7daa5e27

P577

Q28372484-A4F12CAA-1E53-4CEC-835A-D5183FD45318

P698

Q28372484-6D88CF3E-BBEC-4C48-9D11-17CD7CD71138

P932

Q28372484-F2CFB68C-B912-4B6D-9F92-FECD8014CA61

P3181

P356

JCO.2009.22.4725

P1433

Journal of Clinical Oncology

P1476

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

@en

P2093

Alexander Miron

http://www.w3.org/2001/XMLSchema#string

Andrea L Richardson

http://www.w3.org/2001/XMLSchema#string

Aquila Fatima

http://www.w3.org/2001/XMLSchema#string

Arcangela De Nicolo

http://www.w3.org/2001/XMLSchema#string

Ayodele Buraimoh

http://www.w3.org/2001/XMLSchema#string

Chee-Onn Leong

http://www.w3.org/2001/XMLSchema#string

Christian Colin

http://www.w3.org/2001/XMLSchema#string

Daniel P Silver

http://www.w3.org/2001/XMLSchema#string

Dennis C Sgroi

http://www.w3.org/2001/XMLSchema#string

Diana Calogrias

http://www.w3.org/2001/XMLSchema#string

P2860

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Molecular portraits of human breast tumours

Repeated observation of breast tumor subtypes in independent gene expression data sets

Analyzing real-time PCR data by the comparative C(T) method

Genetic analysis of BRCA1 function in a defined tumor cell line

X chromosomal abnormalities in basal-like human breast cancer

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

P304

1145-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

732063

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2009.22.4725

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Aron Charles Eklund

Zoltan Szallasi

Nicolai J Birkbak

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20100965

http://www.w3.org/2001/XMLSchema#string

P932

2834466

http://www.w3.org/2001/XMLSchema#string